undamentalytics Newsletter

Niagen Bioscience, Inc. insider trading

Every open-market purchase and sale by Niagen Bioscience, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Niagen Bioscience, Inc. insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Niagen Bioscience, Inc.’s insiders pay?

From October 4, 2010 to November 17, 2025, 19 insiders reported 52 open-market purchases and 6 sales not made under a pre-set plan in Niagen Bioscience, Inc. Twelve months after each purchase was reported, the shares were −51.4% against the S&P 500 on average (median −50.5%), over 3 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −49.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 22, 2017 into $426 by November 2, 2026, −29.8% a year. It held shares 44% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,833 (+4.5% a year), and held throughout $33,425 (+14.5%).

$0$10.0k$20.0k$30.0k 20172019202120232025 $33.4k$14.8k$426
Copying Niagen Bioscience, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Niagen Bioscience, Inc.'s insiders from November 22, 2017, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 44% of the time.
Niagen Bioscience, Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Honig Barry C Director 9 — — 0 — April 30, 2013
Fried Robert N Cheif Executive Officer 8 −76.9% (1) 0% 0 — October 3, 2022
Farr Kevin M CHIEF FINANCIAL OFFICER 7 — — 0 — November 6, 2020
Jaksch Frank L Jr EXECUTIVE CHAIRMAN OF BOARD 3 — — 3 −28.2% (2) December 13, 2024
Spengler William PRESIDENT 4 — — 0 — December 8, 2011
Brauser Michael Director 3 — — 0 — May 14, 2013
Mayspin Management Ltd 10% owner 3 −50.5% (1) 0% 0 — November 21, 2017
Pioneer Step Holdings Ltd 10% owner 3 — — 0 — October 3, 2022
Block Stephen A Director 0 — — 2 −92.9% (1) March 17, 2021
Frost Gamma Investments Trust 10% owner 2 — — 0 — February 4, 2011
Frost Phillip Md Et Al 10% owner 2 — — 0 — June 21, 2012
Pamir Ozan Chief Financial Officer 2 −26.8% (1) 0% 0 — November 17, 2025
Chau Hoi Shuen Solina Holly 10% owner 1 — — 0 — June 21, 2022
Friedman Mark J GENERAL COUNSEL 1 — — 0 — May 17, 2018
Halpryn Glenn L Director 1 — — 0 — February 14, 2012
Himmel Jeffrey CHIEF EXECUTIVE OFFICER 1 — — 0 — February 14, 2012
Patrick Kristin Director 0 — — 1 — August 26, 2024
Rhonemus Troy Allen CHIEF OPERATING OFFICER 1 — — 0 — June 21, 2016
Rubin Steven D Director 1 — — 0 — May 30, 2023

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Niagen Bioscience, Inc. · Funds · Politicians